Document Detail


CYP4A11 polymorphism correlates with coronary endothelial dysfunction in patients with coronary artery disease--the ENCORE Trials.
MedLine Citation:
PMID:  19615687     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Cytochrome P450 (CYP) is expressed in the human endothelium and metabolizes arachidonic acid into vasoactive epoxyeicosatrienoic and 20-hydroxyeicosatetraenoic acids. CYP enzymes have been linked to hypertension and generation of reactive oxygen species. Thus, we investigated the impact of several CYP polymorphisms on coronary endothelial function in patients with coronary artery disease (CAD). METHODS AND RESULTS: We determined CYP4A11 F434S, CYP2C9 I359L, CYP2C9 G144C and CYP 2J2 promotor -50G>T polymorphisms in 734 patients with CAD undergoing percutaneous coronary intervention. Increasing concentrations of acetylcholine were infused in a coronary segment without angiographically significant CAD and the coronary artery vasomotor response was measured by quantitative angiography. Patients with substitution of phenylalanine 434 by serine (434SS, n=15, 2.04%) in CYP4A11 F434 demonstrated significantly augmented endothelium-dependent vasoconstriction (p=0.044 after Bonferroni correction) compared to patients with the 434FS (n=193, 26.29%) and 434FF genotype (n=526, 71.66%) before and after adjustment for blood pressure and HDL-cholesterol. In addition, patients with the 434SS genotype had higher systolic blood pressure levels (p=0.039) compared to the two other groups. The CYP 2C9 and CYP 2J2 polymorphisms did not show any correlation with coronary vasoconstriction, hypertension, diabetes mellitus, blood pressure or cholesterol. CONCLUSION: In patients with established and stable coronary artery disease the 434SS variant of CYP4A11 F434 is associated with pronounced coronary vasoconstriction.
Authors:
M Hermann; J P Hellermann; K Quitzau; M M Hoffmann; T Gasser; T Meinertz; T M??nzel; I Fleming; T F L??scher
Related Documents :
6311227 - [125i]ldl uptake in rabbit arteries perfused in situ. effect of hdl on intact and de-en...
17202417 - Mineral metabolism and arterial functions in end-stage renal disease: potential role of...
12706187 - Equivalence of plaque score and intima-media thickness of carotid ultrasonography for p...
11195607 - Association between calcific aortic stenosis and hypercholesterolemia: is there a need ...
6138777 - Adrenalectomy potentiates drinking induced by renal artery constriction.
21956607 - Impact of sildenafil on survival of patients with idiopathic pulmonary arterial hyperte...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-06-17
Journal Detail:
Title:  Atherosclerosis     Volume:  207     ISSN:  1879-1484     ISO Abbreviation:  Atherosclerosis     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-11-30     Completed Date:  2010-01-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0242543     Medline TA:  Atherosclerosis     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  476-9     Citation Subset:  IM    
Affiliation:
Klinik f??r Kardiologie, Universit??tsspital, Z??rich, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetylcholine / administration & dosage
Aged
Aryl Hydrocarbon Hydroxylases / genetics
Biological Markers / blood
Blood Pressure / genetics
Clinical Trials as Topic
Coronary Angiography
Coronary Artery Disease / enzymology,  genetics*,  physiopathology,  radiography
Coronary Vessels / drug effects,  enzymology*,  physiopathology
Creatinine / blood
Cytochrome P-450 Enzyme System / genetics*,  metabolism
Endothelium, Vascular / drug effects,  enzymology*,  physiopathology
Female
Genetic Predisposition to Disease
Humans
Kidney / physiopathology
Male
Middle Aged
Phenotype
Polymorphism, Genetic*
Promoter Regions, Genetic
Vasoconstriction / drug effects,  genetics*
Chemical
Reg. No./Substance:
0/Biological Markers; 51-84-3/Acetylcholine; 60-27-5/Creatinine; 9035-51-2/Cytochrome P-450 Enzyme System; EC 1.14.14.1/Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1/CYP2C9 protein, human; EC 1.14.14.1/arachidonate epoxygenase; EC 1.14.15.3/CYP4A11 protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cyclooxygenase-2 derived thromboxane A(2) and reactive oxygen species mediate flow-induced constrict...
Next Document:  Multi-method for the determination of antibiotics of different substance groups in milk and validati...